BeiGene
BGNEBeiGene, Ltd. (NASDAQ: BGNE) is a global biotechnology company headquartered in China. Its primary business focus is the discovery, development, manufacturing, and commercialization of medicines for the treatment of cancer. The company operates on a global scale, with commercial teams in markets including the United States, China, and the European Union, and employs over 10,000 people worldwide. Its research and development efforts are supported by internal capabilities and a portfolio of approved and investigational compounds. The company's key therapeutic area is oncology. BeiGene has developed and commercializes several internally discovered and in-licensed oncology therapies. Its portfolio includes FDA-approved medicines such as BRUKINSA® (zanubrutinib), a Bruton’s tyrosine kinase (BTK) inhibitor for various B-cell malignancies, and tislelizumab, an anti-PD-1 monoclonal antibody immunotherapy. The company's clinical development program encompasses a broad pipeline of drug candidates, both as monotherapies and in combinations, targeting a range of solid tumors and hematologic cancers. To support its global operations, BeiGene has established substantial manufacturing infrastructure. This includes multiple production facilities, with a large-scale biologics manufacturing center in Guangzhou, China, and a flagship Princeton, New Jersey facility in the United States. This integrated approach allows the company to control the end-to-end supply chain for its products, from clinical development through commercial supply.
About
BeiGene, Ltd. (NASDAQ: BGNE) is a global biotechnology company headquartered in China. Its primary business focus is the discovery, development, manufacturing, and commercialization of medicines for the treatment of cancer. The company operates on a global scale, with commercial teams in markets including the United States, China, and the European Union, and employs over 10,000 people worldwide. Its research and development efforts are supported by internal capabilities and a portfolio of approved and investigational compounds. The company's key therapeutic area is oncology. BeiGene has developed and commercializes several internally discovered and in-licensed oncology therapies. Its portfolio includes FDA-approved medicines such as BRUKINSA® (zanubrutinib), a Bruton’s tyrosine kinase (BTK) inhibitor for various B-cell malignancies, and tislelizumab, an anti-PD-1 monoclonal antibody immunotherapy. The company's clinical development program encompasses a broad pipeline of drug candidates, both as monotherapies and in combinations, targeting a range of solid tumors and hematologic cancers. To support its global operations, BeiGene has established substantial manufacturing infrastructure. This includes multiple production facilities, with a large-scale biologics manufacturing center in Guangzhou, China, and a flagship Princeton, New Jersey facility in the United States. This integrated approach allows the company to control the end-to-end supply chain for its products, from clinical development through commercial supply.